Publication: Post translational activation of latent transforming growth factor beta (L-TGF-O): clinical implications
Authors
Khalil, N.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Transforming growth factor-betas (TGF-Bs)
are multifunctional cytokines that exist in 3 isoforms in
mammals. The TGF-Bs are ubiquitously expressed and
al1 isoforms are secreted as biologically inactive
precursors called latent TGF-B (L-TGF- B). LTGF-Bs
are generally not effective molecules because they are
unable to interact with their receptors. However, the
removal of or conformational change of the precursor
protein called the latency associated peptide (LAP)
results in the generation of biologically active TGF- B. Zn
vitro active TGF-B has many biological effects but from
a clinical point of view one of the most recognized
associations of aberrant TGF-B production is with
diseases characterized by enhanced connective tissue
synthesis. Recently a number of observations in the
context of fibrotic disorders suggest mechanisms of
activation of L-TGF-61 in vivo. The recognition of
mechanisms that activate L-TGF-81 in vivo offers the
possibiiity of interfering with the activation of L-TGFB1
for therapeutic purposes.
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.